Background: The risk of bleeding and stroke/systemic embolism (SE) events associated with
apixaban vs. warfarin among oral anticoagulant-naïve Japanese patients with non-valvular …

Objective: To investigate the risk of bleeding events and stroke/systemic embolism (SE)
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …

Background We previously conducted a retrospective cohort study using chart review of oral
anticoagulant-naïve Japanese patients with nonvalvular atrial fibrillation (NVAF) that …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …

Objectives: There is scarce evidence comparing novel oral anticoagulants (NOACs) with
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …

Background No real‐world data exist on outcomes in patients on anticoagulants and
concomitant antiarrhythmic medications. This study aims to compare the safety and …

Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …

East Asians are reportedly at high risk of anticoagulant-related bleeding; therefore, some
physicians prefer to prescribe low-dose direct oral anticoagulants (DOACs). Little is known …

Background: Guidelines recommend warfarin as the standard of care for patients with atrial
fibrillation (AF) at moderate or high risk for stroke. This phase II study assessed the effects of …